Latest news with #WomenLeadHere
Yahoo
31-03-2025
- Business
- Yahoo
Aurora Cannabis Recognized for Executive Gender Diversity by The Globe and Mail
Canada's Largest Medical Cannabis Company is an Honouree in The Globe and Mail's 2025 Report on Business Magazine's sixth annual Women Lead Here List EDMONTON, AB, March 31, 2025 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, has been named an honouree on the Globe & Mail's 2025 Report on Business, Women Lead Here list. This annual editorial benchmark recognizes the top publicly traded Canadian companies with the highest gender diversity at the executive level. "As a company with a leading purpose of being empowered by people, this recognition demonstrates how we are committed to creating an environment where everyone is inspired to strive for excellence," says Simona King, Chief Financial Officer at Aurora. "With 43% of our executive leadership team being women, together the women of Aurora are driving change, breaking barriers and shaping the future for women in the medical cannabis industry." In 2022, the company established the Women Empowerment Network (WEN) – an employee resource group designed to bring together the global Aurora team to enrich the advancement of women. WEN, along with other affinity groups, is open to all employees and offers frequent learning and community engagement opportunities that support personal and professional growth. Aurora is proud to foster a diverse community of industry-leading professionals. As a company that prioritizes cultivating great talent, together the global organization empowers everyone to be their authentic selves, celebrate their differences and continue creating a more equitable and inclusive future. The 2025 Women Lead Here list is published in the April 2025 issue of Report on Business magazine, distributed with The Globe and Mail on March 29, 2025, and online at About Aurora Cannabis Inc. Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co., as well as international brands, Pedanios, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at and follow us on X and LinkedIn. Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB". Contact For Investors: ICR, Inc. | aurora@ About The Globe and Mail The Globe and Mail is Canada's foremost news media company, leading the national discussion and causing policy change through brave and independent journalism since 1844. With our award-winning coverage of business, politics and national affairs, The Globe and Mail newspaper reaches 6.1 million readers every week in our print or digital formats, and Report on Business magazine reaches 2.8 million readers in print and digital every issue. Our investment in innovative data science means that as the world continues to change, so does The Globe. The Globe and Mail is owned by Woodbridge, the investment arm of the Thomson family. Forward Looking Information This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations (with respect to the Transaction and more generally with respect to future acquisitions), management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 20, 2024 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at and filed with and available on the SEC's website at The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. View original content to download multimedia: SOURCE Aurora Cannabis Inc. View original content to download multimedia:
Yahoo
31-03-2025
- Business
- Yahoo
ISC Earns Globe and Mail's 2025 Women Lead Here Benchmark for Sixth Consecutive Year
ISC has been named to the Women Lead Here list every year since its inception in 2020. 44 per cent of ISC's executive leaders identified as women throughout 2024, reflecting sustained progress in gender diversity. REGINA, Saskatchewan, March 28, 2025 (GLOBE NEWSWIRE) -- Information Services Corporation (TSX:ISC) ('ISC' or the 'Company'), is pleased to announce its inclusion in the Globe and Mail's 2025 Women Lead Here for the sixth consecutive year. This recognition highlights ISC's strong leadership team and depth of experience and expertise within the organization. Women Lead Here evaluates executive teams based on the representation of women in senior leadership roles. In 2024, women made up 44 per cent of the executive leadership team throughout ISC and its wholly owned subsidiaries. 'Being recognized for the sixth year in a row is a testament to ISC's strong leadership and commitment to excellence,' said Catherine McLean Vice-President of People and Culture. 'We believe in building a workplace where talent and dedication drive success. Our leadership team reflects that mindset, and we're proud to see women in key roles shaping the future of our business.' For the 2025 ranking, Report on Business assessed hundreds of Canadian companies based on leadership composition, company performance and year-over-year progress. A total of 98 companies earned the Women Lead Here designation, which recognizes organizations making measurable, systemic advancements toward executive gender parity in Canada. The ranking is determined using a proprietary research methodology that assesses tangible progress in fostering diverse and equitable leadership teams. The 2024 Women Lead Here list can be found in the April 2025 issue of Report on Business magazine, distributed with The Globe and Mail on Saturday March 29, 2025, and online at About ISCHeadquartered in Canada, ISC is a leading provider of registry and information management services for public data and records. Throughout our history, we have delivered value to our clients by providing solutions to manage, secure and administer information through our Registry Operations, Services and Technology Solutions segments. ISC is focused on sustaining its core business while pursuing new growth opportunities. The Class A Shares of ISC trade on the Toronto Stock Exchange under the symbol ISC. Media ContactJodi BosnjakExternal Communications SpecialistToll Free: 1-855-341-8363 in North America or in to access your portfolio
Yahoo
28-03-2025
- Business
- Yahoo
Knight Therapeutics Inc. ranks on The Globe and Mail's sixth-annual Women Lead Here benchmark of executive gender diversity
MONTREAL, March 28, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ('Knight' or 'the Company') is pleased to announce it will be recognized on The Globe and Mail's 2025 Report on Business magazine's sixth annual Women Lead Here list. This annual editorial benchmark identifies top-level Canadian businesses with the highest executive gender diversity. 'We are both proud and humble to have Knight Therapeutics Inc. once again featured on the Globe and Mail's Report on Canada's Women Lead Here, as one of the top companies for executive gender diversity within the Canadian corporate landscape and specialty pharmaceutical sector,' said Samira Sakhia, President and Chief Executive Officer of Knight. 'A culture of diversity is at the core of Knight's values, and we remain committed to fostering these principles every day, both within our company and in our unwavering dedication to improving the lives of patients'. The Women Lead Here benchmark was established in 2020 by Report on Business magazine and applies a proprietary research methodology to provide an overview of the largest Canadian corporations with the highest degree of gender diversity among executive ranks. The ranked companies have made tangible and organizational progress related to executive gender parity. For the 2025 ranking, Report on Business conducted a journalistic analysis of approximately 500 large publicly-traded Canadian companies based on revenue, evaluating the ratio of female-identifying to male-identifying executives in the top three tiers of executive leadership. The resultant data was applied to a weighted formula that also factored in company performance, diversity and year-to-year change. In total, 93 companies earned the 2025 Women Lead Here seal, with a combined average of 46% of executive roles held by female-identifying individuals. The 2025 Women Lead Here list is published in the April 2025 issue of Report on Business magazine, distributed with The Globe and Mail on March 29, 2025 and online at About The Globe and Mail The Globe and Mail is Canada's foremost news media company, leading the national discussion and causing policy change through brave and independent journalism since 1844. With our award-winning coverage of business, politics and national affairs, The Globe and Mail newspaper reaches 6.1 million readers every week in our print or digital formats, and Report on Business magazine reaches 2.8 million readers in print and digital every issue. Our investment in innovative data science means that as the world continues to change, so does The Globe. The Globe and Mail is owned by Woodbridge, the investment arm of the Thomson family. About Knight Therapeutics Inc. Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at or Forward-Looking Statement This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2024, as filed on Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law. Investor Contact: Knight Therapeutics Inc. Samira Sakhia Arvind Utchanah President & Chief Executive Officer Chief Financial Officer T: 514.484.4483 T. +598.2626.2344 F: 514.481.4116 Email: IR@ Email: IR@ Website: Website:
